155 related articles for article (PubMed ID: 34084482)
1. Epidermal growth factor receptor inhibitor in advanced basal cell carcinoma.
Amirabadi A; Alami A; Ahanchian H; Ariaee N; Moazzen N
Clin Case Rep; 2021 May; 9(5):e04021. PubMed ID: 34084482
[TBL] [Abstract][Full Text] [Related]
2. Update of cetuximab for non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Monoclonal Antibody Cetuximab Targeting Epidermal Growth Factor-Receptor in Advanced Non-Melanoma Skin Cancer.
Wollina U; Tchernev G; Lotti T
Open Access Maced J Med Sci; 2018 Jan; 6(1):152-155. PubMed ID: 29484016
[TBL] [Abstract][Full Text] [Related]
4. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
5. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
6. Combined paclitaxel and cetuximab achieved a major response on the skin metastases of a patient with epidermal growth factor receptor-positive, estrogen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast cancer.
Gholam D; Chebib A; Hauteville D; Bralet MP; Jasmin C
Anticancer Drugs; 2007 Aug; 18(7):835-7. PubMed ID: 17581308
[TBL] [Abstract][Full Text] [Related]
7. Cetuximab in non-melanoma skin cancer.
Wollina U
Expert Opin Biol Ther; 2012 Jul; 12(7):949-56. PubMed ID: 22519406
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.
Cripps C; Winquist E; Devries MC; Stys-Norman D; Gilbert R;
Curr Oncol; 2010 Jun; 17(3):37-48. PubMed ID: 20567625
[TBL] [Abstract][Full Text] [Related]
9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
10. Cetuximab in refractory skin cancer treatment.
Kalapurakal SJ; Malone J; Robbins KT; Buescher L; Godwin J; Rao K
J Cancer; 2012; 3():257-61. PubMed ID: 22712026
[TBL] [Abstract][Full Text] [Related]
11. Case Report: Cetuximab use in advanced cutaneous squamous cell carcinoma resistant to chemotherapy.
Sernicola A; Lampitelli S; Marraffa F; Maddalena P; Grassi S; Richetta AG; Calvieri S
F1000Res; 2019; 8():933. PubMed ID: 32047600
[TBL] [Abstract][Full Text] [Related]
12. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Neal JW; Heist RS; Fidias P; Temel JS; Huberman M; Marcoux JP; Muzikansky A; Lynch TJ; Sequist LV
J Thorac Oncol; 2010 Nov; 5(11):1855-8. PubMed ID: 20975380
[TBL] [Abstract][Full Text] [Related]
14. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
[TBL] [Abstract][Full Text] [Related]
15. Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Ramalingam S; Forster J; Naret C; Evans T; Sulecki M; Lu H; Teegarden P; Weber MR; Belani CP
J Thorac Oncol; 2008 Mar; 3(3):258-64. PubMed ID: 18317068
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy with cetuximab versus chemotherapy alone for chemotherapy-naive advanced non-small cell lung cancer.
Yang ZY; Liu L; Mao C; Wu XY; Huang YF; Hu XF; Tang JL
Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD009948. PubMed ID: 25400254
[TBL] [Abstract][Full Text] [Related]
17. Concomitant cetuximab and radiation therapy: A possible promising strategy for locally advanced inoperable non-melanoma skin carcinomas.
Della Vittoria Scarpati G; Perri F; Pisconti S; Costa G; Ricciardiello F; Del Prete S; Napolitano A; Carraturo M; Mazzone S; Addeo R
Mol Clin Oncol; 2016 Apr; 4(4):467-471. PubMed ID: 27073643
[TBL] [Abstract][Full Text] [Related]
18. Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor.
Sasaki K; Anderson E; Shankland SJ; Nicosia RF
Am J Kidney Dis; 2013 Jun; 61(6):988-91. PubMed ID: 23474009
[TBL] [Abstract][Full Text] [Related]
19. New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer.
Savoia P; Cremona O; Fava P
Curr Drug Targets; 2016; 17(3):353-74. PubMed ID: 26245477
[TBL] [Abstract][Full Text] [Related]
20. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
